BSX Stock Overview
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
NewNotes are coming soon
Boston Scientific Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$45.91 |
| 52 Week High | US$47.95 |
| 52 Week Low | US$34.98 |
| Beta | 0.81 |
| 1 Month Change | -0.78% |
| 3 Month Change | 6.49% |
| 1 Year Change | 7.42% |
| 3 Year Change | 9.65% |
| 5 Year Change | 67.62% |
| Change since IPO | 972.35% |
Recent News & Updates
Boston Scientific sees double digit EPS growth in 2023 - JPMorgan Healthcare conference
Jan 11Boston Scientific to acquire majority stake of Acotec Scientific
Dec 12Recent updates
What Does Boston Scientific Corporation's (NYSE:BSX) Share Price Indicate?
Oct 03
There Are Reasons To Feel Uneasy About Boston Scientific's (NYSE:BSX) Returns On Capital
Sep 19These 4 Measures Indicate That Boston Scientific (NYSE:BSX) Is Using Debt Reasonably Well
Aug 21Boston Scientific Corporation (NYSE:BSX) Shares Could Be 23% Below Their Intrinsic Value Estimate
Jul 27Is Now An Opportune Moment To Examine Boston Scientific Corporation (NYSE:BSX)?
Jul 01Boston Scientific (NYSE:BSX) Will Want To Turn Around Its Return Trends
Jun 17Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
May 20An Intrinsic Calculation For Boston Scientific Corporation (NYSE:BSX) Suggests It's 20% Undervalued
Apr 23What Is Boston Scientific Corporation's (NYSE:BSX) Share Price Doing?
Mar 18Is Boston Scientific (NYSE:BSX) Using Too Much Debt?
Feb 09Be Wary Of Boston Scientific (NYSE:BSX) And Its Returns On Capital
Jan 22An Intrinsic Calculation For Boston Scientific Corporation (NYSE:BSX) Suggests It's 21% Undervalued
Jan 09Is Now An Opportune Moment To Examine Boston Scientific Corporation (NYSE:BSX)?
Dec 14Boston Scientific (NYSE:BSX) Has A Rock Solid Balance Sheet
Nov 05Here's What To Make Of Boston Scientific's (NYSE:BSX) Decelerating Rates Of Return
Oct 23A Look At The Intrinsic Value Of Boston Scientific Corporation (NYSE:BSX)
Oct 08Shareholder Returns
| BSX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0.6% | -0.2% | 2.8% |
| 1Y | 7.4% | -9.7% | -9.2% |
Return vs Industry: BSX exceeded the US Medical Equipment industry which returned -9.7% over the past year.
Return vs Market: BSX exceeded the US Market which returned -9.2% over the past year.
Price Volatility
| BSX volatility | |
|---|---|
| BSX Average Weekly Movement | 2.8% |
| Medical Equipment Industry Average Movement | 8.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: BSX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BSX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 41,000 | Mike Mahoney | https://www.bostonscientific.com |
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems.
Boston Scientific Corporation Fundamentals Summary
| BSX fundamental statistics | |
|---|---|
| Market Cap | US$65.76b |
| Earnings (TTM) | US$597.00m |
| Revenue (TTM) | US$12.57b |
110.1x
P/E Ratio5.2x
P/S RatioIs BSX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSX income statement (TTM) | |
|---|---|
| Revenue | US$12.57b |
| Cost of Revenue | US$3.85b |
| Gross Profit | US$8.72b |
| Other Expenses | US$8.12b |
| Earnings | US$597.00m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
Feb 01, 2023
| Earnings per share (EPS) | 0.42 |
| Gross Margin | 69.37% |
| Net Profit Margin | 4.75% |
| Debt/Equity Ratio | 48.6% |
How did BSX perform over the long term?
See historical performance and comparison